On November 13, the Brazilian company Biomm announced an agreement with the Chinese pharmaceutical company Gan & Lee Pharmaceuticals for the marketing and distribution of insulin aspart in Brazil.

This is the second agreement signed between the two companies. In 2021, the Biomm began marketing the insulin glargine of Gan & Lee Pharmaceuticals under the brand Glargilin.

Insulin Aspart is an ultra-rapid-acting insulin analogue indicated for the treatment of diabetes mellitus, the company states.  The product can be used in combination with intermediate or long-acting insulins.

“With the cooperation with the Chinese pharmaceutical company, the company expands its portfolio and reinforces its commitment to improving access for chronic diseases”, says Biomm.

(Source: website of Biomm, on November 13)